BioXcel Therapeutics, Inc.
BTAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.3% | -28.6% | -54.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 12.2% | 10.8% | 91.7% | -127.3% |
| R&D Expenses | $9 | $10 | $5 | $6 |
| G&A Expenses | $0 | $6 | $6 | $4 |
| SG&A Expenses | $5 | $6 | $6 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $16 | $10 | $10 |
| Operating Income | -$14 | -$16 | -$10 | -$10 |
| % Margin | -14,212.2% | -13,210% | -6,011.3% | -2,866.9% |
| Other Income/Exp. Net | -$17 | -$3 | $3 | -$0 |
| Pre-Tax Income | -$31 | -$19 | -$7 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$31 | -$19 | -$7 | -$11 |
| % Margin | -31,541.8% | -15,989.2% | -4,317.9% | -2,966.9% |
| EPS | -2.18 | -2.45 | -1.5 | -3.57 |
| % Growth | 11% | -63.3% | 58% | – |
| EPS Diluted | -2.18 | -2.45 | -1.5 | -3.57 |
| Weighted Avg Shares Out | 14 | 8 | 5 | 3 |
| Weighted Avg Shares Out Dil | 14 | 8 | 5 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $4 | $4 | $0 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$15 | -$3 | -$7 |
| % Margin | -27,003.1% | -12,408.3% | -1,895.8% | -1,844.3% |